Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JQ1 + unspecified PD-L1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JQ1 | JQ-1 | BET Inhibitor (Pan) 32 | JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568, PMID: 32800944). | |
unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 del | prostate cancer | sensitive | JQ1 + unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, the combination of JQ1 and an anti-PD-L1 therapy inhibited tumor growth in a syngeneic mouse model of RB1-deficient prostate cancer (PMID: 37014264). | 37014264 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|